Anti-transferrin receptor antibodies with optimized CDR sequences
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved anti-transferrin receptor antibodies for pharmaceutical uses, particularly for targeted cancer diagnostics and therapeutics, as existing antibodies may not effectively address the overexpression of transferrin receptor 1 in various cancers.
Innovation Solution
Development of anti-transferrin receptor antibodies with specific variable heavy and light chain regions, including HCDR and LCDR sequences, and their conjugates with payloads such as small molecules, peptides, or polynucleic acids, designed for targeted delivery and treatment of cancers and muscle atrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-transferrin receptor antibodies are used for targeted cancer diagnostics and therapeutics, then the transferrin receptor can be targeted, but the therapeutic effectiveness is insufficient due to inadequate binding affinity or specificity
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody's variable region sequences (HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3) to achieve superior binding affinity and specificity for transferrin receptor 1. The specific amino acid sequences in the CDR regions are engineered to enhance therapeutic effectiveness while maintaining a manageable structural framework.
Solution Approach 2:
The patent employs composite materials by creating chimeric or humanized antibody constructs that combine different sequence elements. These composite antibody structures integrate optimized CDR regions from different sources into a unified molecular architecture, achieving both high therapeutic effectiveness and reduced immunogenicity.
2Measurement precision
If anti-transferrin receptor antibodies are developed with optimized variable regions, then binding specificity to transferrin receptor 1 is improved, but the development complexity and manufacturing difficulty increase
Solution Approach 1:
The patent applies segmentation by dividing the antibody into distinct functional regions with optimized sequences. The variable heavy chain (VH) and variable light chain (VL) regions are segmented into framework regions and complementarity-determining regions (CDR1, CDR2, CDR3), allowing independent optimization of binding specificity while facilitating standardized manufacturing protocols for each segment.
Solution Approach 2:
The patent achieves universality by designing antibody constructs with conserved framework regions that can be manufactured using standardized protocols, while the variable CDR regions provide specific binding functionality. This multi-functional design allows the same manufacturing platform to produce antibodies with different specificities by simply changing the CDR sequences.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies and conjugates specifically bind to transferrin receptors, enabling targeted delivery of payloads to cancer cells and muscle tissues, potentially offering improved therapeutic outcomes for cancers and muscle disorders.
Implementation Method 1
The antibodies and conjugates specifically bind to transferrin receptors
Data Source
AI summary
Disclosed herein, in certain embodiments, are anti-transferrin receptor antibodies, anti-transferrin receptor antibody conjugates, and pharmaceutical compositions which comprise the anti-transferrin receptor antibodies or conjugates. In some embodiments, also disclosed herein are methods of delivering a payload utilizing an anti-transferrin receptor antibody described herein, and methods of treatment with use of an anti-transferrin receptor antibody described herein.